Rapport therapeutics hosts investor and analyst day; provides corporate updates

Phase 2a trial of rap-219 in refractory focal epilepsy fully enrolled and on track for topline results in september 2025 phase 2a trial of rap-219 in refractory focal epilepsy fully enrolled and on track for topline results in september 2025

RAPP Ratings Summary

RAPP Quant Ranking